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While physical activity during cancer treatment is found beneficial for breast cancer patients, evidence indicates ambiguous findings
concerning effects of scheduled exercise programs on treatment-related symptoms. This study investigated effects of a scheduled
home-based exercise intervention in breast cancer patients during adjuvant chemotherapy, on cancer-related fatigue, physical
fitness, and activity level. Sixty-seven women were randomized to an exercise intervention group (𝑛 = 33, performed strength
training 3x/week and 30 minutes brisk walking/day) and a control group (𝑛 = 34, performed their regular physical activity
level). Data collection was performed at baseline, at completion of chemotherapy (Post
1
), and 6-month postchemotherapy (Post
2
).
Exercise levels were slightly higher in the scheduled exercise group than in the control group. In both groups, cancer-related fatigue
increased at Post
1
but returned to baseline at Post
2
. Physical fitness and activity levels decreased at Post
1
but were significantly
improved at Post
2
. Significant differences between intervention and control groups were not found. The findings suggest that
generally recommended physical activity levels are enough to relief cancer-related fatigue and restore physical capacity in breast
cancer patients during adjuvant chemotherapy, although one cannot rule out that results reflect diminishing treatment side effects
over time.
1. Introduction
Physical activity guidelines recommend healthy individ-
uals to perform 150 minutes⋅wk
1
of at least moderate-
intensity physical activity (MVPA), in order to obtain health-
promoting effects [1]. Breast cancer survivors are advised
to avoid inactivity and to follow the same age-appropriate
guidelines as healthy individuals [2].The effects of exercise on
treatment-related issues in cancer patients may fade rapidly
if not maintained or if the exercise is not sufficient enough
[3]. Thus, evaluating the patients’ adherence to physical
activity guidelines is important. However, as shown by others,
many cancer patients reduce their physical activity after the
diagnosis, or they exercise less than recommended [4]. A
study of 1,696 breast cancer survivors found a decrease in
metabolic equivalent of task (MET) hours perweek by amean
of −9.40 (27.94), corresponding to 30 minutes of MVPA 4.7
days per week [5].
It has been reported that receiving chemotherapy is one
of the strongest independent predictors for reduced physical
activity level [5]. Many patients are offered a combination
of both hormonal and cytotoxic treatments, with or without
trastuzumab. In Norway, adjuvant chemotherapy usually
comprises an 18-week treatment with anthracycline-based
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polychemotherapy (fluorouracil, epirubicin, and cyclophos-
phamide; FEC). Some patients are treated for 3 months with
this combination, followed by a 3-month period of taxane
monotherapy [6]. Due to treatment effects on nonneoplastic
cells, severe physical, emotional, and cognitive treatment-
related symptoms may appear during or shortly after the
delivery of chemotherapy [7, 8]. Cancer-related fatigue is
considered the most prevalent and distressing symptom in
relation to cancer treatment and has been defined as “an
overwhelming sustained sense of exhaustion and decreased
capacity for physical and mental work at usual level” [9]. It
can occur from the time of diagnosis, through treatment,
and is present in about 26–28% of breast cancer patients
following treatment [7]. Studies report that fatigue shows a
high and fluctuating prevalence similar to a roller-coaster
pattern during adjuvant chemotherapy [10] and may be
present for as long as 5 years following treatment with no
improvement during the first two years [7, 10]. Fatigue as a
side effect of the cancer treatment has a negative effect on
physical fitness and physical activity levels [7, 11].
Several physical activity interventions aiming at improv-
ing health outcomes during cancer treatment have been
tested, as demonstrated by the numerous, recent literature
reviews [12–18]. Of seven reviews published between 2007
and 2012, breast cancer patients were the most studied
cancer population, representing from 46–100% of the stud-
ied populations. The reviews identified ambiguous findings
concerning the effect of scheduled exercise interventions
on cancer-related fatigue [14–18]. Considerable heterogeneity
between exercise intervention studies, regarding exercise
mode, outcome measurements, and disease- and treatment-
specific factors, has beenhighlighted as a possible explanation
[15, 18]. Moreover, the reviews give limited information
on recommended exercise dose (i.e., frequency, intensity,
and duration) and do not include comparison of effects of
scheduled exercise interventions as compared to general rec-
ommendations on physical activity [2].This represents a lack
of clarity whether explicit exercise interventions will reduce
negative treatment side effects and give effects additional to
that of simply advising the women to be physically active
according to general recommendations.
In this study, effects of a scheduled home-based exercise
intervention on cancer-related fatigue, physical fitness, and
physical activity level, as compared to being advised to
exercise at a regular physical activity level, was investigated
among breast cancer patients. The exercise intervention
combined resistance and aerobic exercise, to be performed
during chemotherapy treatment. Regular physical activity
level was defined as physical activity in accordance with
general recommendations of 150 minutes/week of MVPA.
We hypothesized that the scheduled exercise intervention
program would significantly reduce cancer related fatigue
and increase physical fitness and physical activity levels
compared to general recommendations of physical activity
and that these changes would be significantly greater in the
intervention group compared to the control group.
2. Methods
2.1. Study Design and Population. The randomized, con-
trolled trial was conducted in one university hospital in
Norway during 2010–2012. Eligible breast cancer patients
were between 18 and 70 years of age, surgically treated for
early stage breast cancer (mastectomy or lumpectomy), and
allocated to adjuvant chemotherapy according to the national
treatment guidelines of the Norwegian Breast Cancer Group.
The included patients had to be able to read, write, and speak
Norwegian, and they were approved for participation in this
study by a clinical oncologist. The random assignment of
subjects to the intervention group or to the control group was
carried out by the use of concealed envelops, drawn by the
research assistant prior to the first data collection.
2.2. Ethics. The study was conducted in accordance with
the Declaration of Helsinki (1964), and approved by the
Norwegian Regional Committees for Medical and Health
Research Ethics (Reg. No. 2009/2283). All participants gave
their volitional, written consent based on both verbal and
written information on the characteristics of the intervention
program and assessment procedures provided by the clinic
staff.
2.3. Data Collection Procedures. The study sample completed
questionnaires and physical tests after surgery prior to
chemotherapy (baseline), 18–24 weeks after baseline and at
the end of chemotherapy (Post
1
), and approximately six
months after completing the chemotherapy regimen (Post
2
).
Demographic characteristics were obtained by a question-
naire (age, body weight, height, ethnicity, marital status,
living conditions, education, and employment). Clinical data
were retrieved from the hospital records (diagnosis, can-
cer stage, surgical treatment, lymph node status, hormone
receptor status, adjuvant treatment, previous cancer history,
and other health conditions). In addition, the questionnaire
provided data on cancer related fatigue and physical activity
levels. Physical fitness was assessed by a physical test, and data
on exercise volume were collected from exercise diaries.
(1) Schwartz Cancer Fatigue Scale (SCFS-6). Cancer-related
fatigue was measured by a revised version of the SCFS-6, a
6-item scale developed to measure cancer specific fatigue on
two dimensions: physical and perceptual and on a 1 “not at
all” to 5 “extremely” scale [19]. Sum scores range from 6 to 30
a higher score indicating the subject feeling more fatigued.
Content and constructs validity and reliability have been
demonstrated, with a Cronbach’s alpha for the total scale of
0.90 [19, 20]. In this study SCFS-6was translated fromEnglish
to Norwegian by a standard back-translation procedure [21].
Two bilingual persons, both fluent inNorwegian and English,
translated and back-translated until agreement was reached.
TheNorwegian version of SCFS-6 was then content validated
by two health professionals and a breast cancer patient.
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A Cronbach’s alpha of 0.83 indicated good internal consis-
tency of the Norwegian version of SCFS-6.
(2) International Physical Activity Questionnaire (IPAQ) Short
Form. Physical activity level was assessed by the IPAQ short
form. The IPAQ short form was employed as a supplement
to exercise diaries, to ensure recording of activity levels
between Post
1
and Post
2
, since the participants did not report
in exercise diaries in this time period. In the IPAQ short
form the participants were asked to recall their physical
activities during the last 7 days [22]. The IPAQ short form
gives information on metabolic equivalent of task (MET)
hours during moderate and vigorous activity and minutes
spent sitting down. IPAQ short form scoring guidelines
provide three physical activity levels: low (i.e., <600 MET-
minutes/week), moderate (i.e., ≥600 MET-minutes/week),
and high (i.e., ≥3000 MET-minutes/week) [23]. Through
extensive reliability and validity testing the IPAQ Executive
Committee has approved the IPAQ short form in many
countries for comparing population estimates for physical
activity [22].
(3) 6-Minute Walk Test (6-MWT). Physical fitness was
assessed by the 6-MWT which measures how far the patient
can quickly walk on a flat, hard surface during a 6-minute
time period. It assesses the patient’s functional capacity on
a sub-maximal level and reflects the exercise level for daily
physical activities [24]. A healthy individual’s 6-MWT range
from 400 to 700 meters (m), and an improvement of more
than 70m is considered to be of clinical importance to the
patient [25].
(4) Exercise Diary. Exercise volume was obtained from exer-
cise diaries, in which the participants in both groups regis-
tered their daily exercise activities and leisure time activities
(e.g., gardening). The registration started at baseline and
lasted until two weeks after the last cycle of chemotherapy.
Weekly exercise minutes were calculated for each activity
type. For the walking regimen, weekly minutes were cal-
culated on all four intensity levels. Total physical activity
intensity categorization was calculated for both groups, and
included strength training with rubber bands, walking, and
additional strength training and aerobic exercise. Examples
of additional strength training were yoga, pilates, and weight
lifting, while examples of additional aerobic exercise were
spinning, jogging, and swimming.
2.4. Exercise Intervention. The intervention consisted of a
home-based exercise program that combined strength and
aerobic training performed throughout the time period of
adjuvant chemotherapy. The strength training prescription
included exercises with resistance bands for arms and legs
and strength training for the upper body, and the subjects
were recommended to perform this training three times per
week.The aerobic prescription consisted of a daily 30minutes
of brisk walking, which could be split into periods of 10-
minutewalks. Patients were instructed to categorize thewalk-
ing intensity in four different intensity levels (light, moderate,
vigorous, and very vigorous) [26]. They were encouraged to
obtain at least moderate intensity during walks. The women
in the intervention group were supported and encouraged
in their exercise by motivational telephone calls from the
research team every second week. The telephone calls were
also used to monitor adverse events. The women in the
control group were encouraged to remain on their regular
activity level and received one follow-up call during the
intervention time period.
2.5. Exercise Adherence. Exercise adherence was defined as
the extent to which the women in the intervention group
performed the exercise program as prescribed, operational-
ized as walking at moderate intensity for at least 30 minutes
per day (i.e., 210 minutes/week) and performing the strength
training program at least three times per week. Data on
adherence was obtained from the exercise diaries.
2.6. Statistical Analysis. A power analysis was performed to
determine the sample size for this study, using the statistical
analysis programG∗Power [27, 28]. Power analyses indicated
a sample size of 38 for medium effect sizes (Cohen’s 𝑓 =
0.25) and 58 when expecting small effect sizes (Cohen’s 𝑓 =
0.20). A planned sample size was set to 60 participants.
Statistical analyses included descriptive analyses, reliability
testing, one-way ANOVA, and a mixed design ANOVA
conducted by the GLM-procedure in SPSS [29]. The mixed
design ANOVA procedure allows a mixture of between-
group and repeated measures variables and thereby tests
the significance of within- and between-group differences
simultaneously.This technique was employed to examine the
effectiveness of the exercise program. In addition, Cohen’s
𝑑 correcting for dependence between means scores was
calculated. Patterns of missing data on the Schwartz Cancer
Fatigue Scale-6 (SCFS-6) were registered by each case for
all three time points. No case had more than two missing
items. Missing items were replaced by a computed mean
based on the scores on the remaining items. Missing data on
the International Physical Activity Scale (IPAQ) short form
were handled by excluding cases missing more than two of
the activity intensities. Cases that reported activity on 1-2
of the intensities and those who reported zero activity on
all three intensity levels remained in the analysis. Statistical
significance was set at 𝑃 < 0.05. A 𝑃 value between
0.05 and 0.1 indicated a tendency. All statistical analyses
were performed using PASW Statistics 18 for Windows
[29]. Inspections of the distributions of dependent variables
revealed that scores for the SCFS-6 and the 6-Minute Walk
Test showed approximately normal distributions and were
suited for parametric statistics. IPAQ short form deviated
somewhat from the normal distribution (skewness 1.73–2.24;
kurtosis 2.75–4.85) and follow-up analysis implementing
scores transformed by the lg10 algorithm was performed.
3. Results
3.1. Patients Characteristics. The flow of participants through
the study is presented in Figure 1. Among 93 consecutive and
eligible breast cancer patients, 67 (72%) patients agreed to
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Figure 1: Flow of breast cancer patients through the trial.
participate and completed the questionnaires and performed
the physical tests at baseline. Seven patients (10.4%)withdrew
from the study before the second data collection at Post
1
,
leaving 60 patients to complete the data collection. At Post
2
,
52 patients (77.6% of the baseline sample) remained in the
study and completed questionnaires and physical tests for
the last time, resulting in a total drop-out rate of 22.4%.
The representativeness of the follow-up sample was tested
by ANOVA and cross-tabulations including chi-square tests.
At baseline the mean age of the women in the intervention
group was 50.8 and 53.6 in the control group. Most of the
women in both groups were of Norwegian origin and living
with a partner. 43.3% of them had children living at home,
and 49.3% were employed. In the intervention group, 59.3%
had a university degree, whilst 35.2% in the control group had
a university degree. Most of the women in both groups had
undergone breast-conserving surgery and were diagnosed
with cancer stage I or II. Half of the women in both groups
received a chemotherapy regimen consisting of both FEC
(i.e., fluorouracil, epirubicin, and cyclophosphamide) and
taxane, and 71.7% of the total sample received radiother-
apy, following the chemotherapy treatment. No significant
difference between those completing the follow-up test and
those that withdrew was found for demographic and clinical
variables, fatigue, 6-Minute Walk Test, and total exercise
volume for moderate to vigorous physical activity. Table 1
shows baseline characteristics of the total study sample and
of the intervention and control group.
3.2. Exercise Volume. Exercise volume recorded in individual
exercise diaries showed that the patients exercised for 17
weeks on average (Table 1), with a mean of 168 (SD 100)
minutes of moderate to vigorous physical activity (MVPA)
perweek.The intervention group had amean exercise volume
of 194 (SD 110) minutes ofMVPA.While 58%met the general
recommendations of 150 minutes/week of MVPA, only 17%
adhered to the walking prescription of minimum 210 min-
utes/week of MVPA. Participants carried out approximately
two sessions of resistance band exercises per week, and 15%
of the participants in the intervention group achieved the
prescribed number of strength training sessions. The control
group had a mean exercise volume of 144 (SD 84) MVPA
minutes per week, and 39% performed 150 minutes/week
of MVPA or more. Data on exercise volume indicates that
48% of participants in both groups exercised according to
the general recommended physical activity level or more.
However, there was a tendency of a significantly larger mean
exercise volume in the intervention group compared to the
control group (𝑃 = 0.051, Cohen’s 𝑑 = 0.52).
Adverse events related to the exercise intervention were
few. One participant in the intervention group reported
knee discomfort and was referred to her primary physician
for further evaluation. The patient stayed in the trial and
completed the exercise prescription. Another participant
in the intervention group experienced syncope during the
walking exercise. This was related to a secondary chronic
condition, and the patient was advised by her oncologist to
withdraw from the trial.
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Table 1: Demographics and characteristics of study population (𝑁 = 67).
Variable Total sample (𝑁 = 67) Intervention group (𝑁 = 33) Control group (𝑁 = 34) 𝑃 value
𝑛 (%) 𝑛 (%) 𝑛 (%)
Age (years) 0.576
Mean ± SD 52.2 ± 9.3 50.8 ± 9.7 53.6 ± 8.8
Body weight (kg) 0.178
Mean ± SD 70.5 ± 13.8 69.0 ± 11.6 72.0 ± 15.7
Waist line (cm) 0.444
Mean ± SD 83.1 ± 11.1 81.6 ± 9.9 84.5 ± 12.0
Living conditions
Living alone 10 (14.9) 5 (15.2) 5 (14.7) 0.510
Living with partner 54 (80.6) 27 (81.8) 27 (79.4) 0.204
Living with others 2 (3.0) 0 (0) 2 (5.9) 0.086
Missing 1 (1.5) 1 (3.0) 0 (0)
Ethnicity 0.638
Norwegian 57 (85.1) 27 (81.8) 30 (88.2)
Other 9 (13.4) 5 (15.6) 4 (11.8)
Missing 1 (1.5) 1 (3.0) 0 (0)
Children living at home 0.205
Yes 29 (43.3) 17 (53.1) 12 (35.3)
No 37 (55.2) 15 (46.9) 22 (65.7)
Missing 1 (1.5) 3.0 (1) 0 (0)
Education 0.186
High school 12 (17.9) 4 (12.5) 8 (23.5)
College 23 (34.3) 9 (28.2) 14 (41.1)
University 31 (46.3) 19 (59.3) 12 (35.2)
Missing 1 (1.5) 1 (3.0) 0.0 (0)
Currently employed 0.331
Yes 19 (28.4) 12 (40.0) 7 (21.2)
Yes, part time 14 (20.9) 5 (16.7) 9 (27.3)
No 30 (44.8) 13 (43.3) 17 (51.5)
Missing 4 (6.0) 3 (9.03) 1 (2.9)
Cancer stagea 0.394
I 19 (31.7) 7 (24.2) 12 (38.7)
II 34 (56.7) 19 (65.5) 15 (48.4)
III 7 (11.6) 3 (10.3) 4 (12.9)
PgR status 0.782
Negative 32 (47.8) 16 (48.5) 16 (47.1)
Positive 35 (52.2) 17 (51.5) 18 (52.9)
ER status 0.464
Negative 21 (31.3) 13 (39.4) 8 (23.5)
Positive 46 (68.7) 20 (60.6) 26 (76.5)
HER-2 status 0.254
Negative 55 (82.0) 26 (78.8) 29 (85.3)
Positive 11 (16.4) 7 (21.2) 4 (11.8)
Missing 1 (1.5) 0.0 (0) 1 (2.9)
Surgery 0.866
Lumpectomy 22 (32.8) 21 (63.6) 24 (70.6)
Mastectomy 45 (67.2) 12 (36.4) 10 (29.4)
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Table 1: Continued.
Variable Total sample (𝑁 = 67) Intervention group (𝑁 = 33) Control group (𝑁 = 34) 𝑃 value
𝑛 (%) 𝑛 (%) 𝑛 (%)
Chemotherapy regimen 0.898
FEC-60 33 (49.3) 16 (48.5) 17 (50.0)
FEC-100 4 (6.0) 2 (6.1) 2 (5.9)
FEC-60 + Taxotere 18 (26.9) 8 (24.2) 10 (29.4)
FEC-100 + Taxotere 5 (7.5) 3 (9.1) 2 (5.9)
FEC-60 + Taxol 7 (10.4) 4 (12.1) 3 (8.8)
Other adjuvant systemic treatment 56 (93.3) 27 (93.1) 29 (93.5) 0.612
Radiotherapy 48 (71.7) 22 (75.9) 26 (83.9)
Intervention duration (weeks) 0.807
Mean ± SD 17.2 ± 7.7 16.7 ± 7.6 17.6 ± 7.9
SD: standard deviation, ER: estrogen receptor, PgR: progesterone receptor, FEC-60: chemotherapy regimen of fluorouracil, epirubicin and cyclophosphamide
administered in 60mg/m2 dosage. FEC-100: chemotherapy regimen of fluorouracil, epirubicin and cyclophosphamide administered in 100mg/m2 dosage,
HER-2: human epidermal growth factor receptor 2.
aCancer stage based on pTNM staging system.
3.3. Cancer-Related Fatigue. In general, low mean fatigue
scores for both the intervention group and the control group
at all three time points (Schwartz Cancer Fatigue Scale-6;
range 6–30) were encountered (see Table 2). The results in
Table 3 show that the fatigue scores increased significantly
from baseline to end of chemotherapy for the whole sample
(𝑃 = 0.003; Cohen’s 𝑑 = 0.41). Comparison of mean
fatigue scores at baseline and Post
2
showed a nonsignificant
difference (𝑃 = 0.181; see Table 4), indicating a return to
baseline levels of fatigue for the total sample. No significant
differences in the trajectory of fatigue between exercise and
control groups were found.
3.4. Physical Activity Level. Physical activity levels measured
by the International Physical Activity Questionnaire-short
form showed that the total sample can be classified as
exercisers at a moderate level of physical activity (i.e., ≥600
metabolic equivalent of task (MET)-minutes/week) at all
three points of measurements (see Table 2). Tables 3 and 4
show that mean levels forMET-minutes/week did not change
significantly from baseline to Post
1
for the total sample but
increased significantly from baseline to Post
2
(𝑃 = 0.00;
Cohen’s 𝑑 = 0.62). No significant differences in changes in
mean levels of MET-minutes/week between the intervention
and control groups were found. Follow-up analysis with lg10
transformed scores yielded results in accordance with those
presented in Tables 3 and 4.
3.5. Physical Fitness. Mean physical fitness measured by the
6-Minute Walk Test (6-MWT) is presented in Table 2, and
results for tests of changes inmean scores between groups and
points of measurement are presented in Tables 3 and 4. For
the total sample physical fitness decreased marginally from
baseline to Post
1
(𝑃 = 0.088), whereas the test of baseline-
Post
2
changes showed a significant increase (𝑃 = 0.009;
Cohen’s 𝑑 = 0.39). No significant differences in changes for
the 6-MWT between the two groups were demonstrated.
4. Discussion
The present study examines effects of a scheduled aerobic
exercise and strength training intervention on cancer-related
fatigue, physical fitness, and physical activity levels during
adjuvant breast cancer chemotherapy compared to general
recommended physical activity. The results provide infor-
mation on exercise dose (frequency, intensity, duration, and
mode) sufficient to relieve treatment-related symptoms and
restore physical capacity in breast cancer patients during
adjuvant chemotherapy.
Although there is inconsistent evidence regarding per-
sistence of cancer-related fatigue [11], it has been found
to be a long-lasting side effect of cancer treatment [7,
30]. A positive finding from our study was that the mean
fatigue levels returned to pretreatment levels 6 months after
the end of chemotherapy in both the intervention group
and the control group. Especially, considering that nearly
72% of our participants received radiotherapy following the
chemotherapy and that radiotherapy is known to cause ele-
vated fatigue levels in breast cancer patients [31], one would
expect increased fatigue levels also at the 6-month followup.
The fatigue experience followed the same trajectory in both
conditions, increasing towards the end of the chemotherapy
time period (Post
1
) and returning to initial assessment levels
6 months after the chemotherapy treatment had been com-
pleted (Post
2
). The pattern of results for physical fitness and
physical activity levels appeared slightly different, showing
a significant improvement in walking distance and activity
levels 6 months after completing the chemotherapy. This
might point towards increased energy levels and can be
described as a consequence of relatively high exercise activity
during treatment in this sample.
As for cancer-related fatigue, physical fitness and physical
activity levels showed the same changes over time in the
intervention group and the control group. The recommen-
dations from American College of Sports Medicine state
are that it is safe and effective for breast cancer patients to
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Table 2: Mean scores and standard deviations for study variables at baseline, end of chemotherapys and 6-month follow-up tests for the
intervention and control groups.
Intervention group Control group
Baseline
(𝑛 = 33)
End of
chemotherapy
Post1 (𝑛 = 29)
Followup
Post2 (𝑛 = 25)
Baseline
(𝑛 = 34)
End of
chemotherapy
Post1 (𝑛 = 31)
Followup
Post2 (𝑛 = 28)
Schwartz Cancer
Fatigue Scale-6a 10.28 (3.93) 12.01 (4.38) 10.43 (3.27) 11.36 (3.56) 13.13 (4.47) 10.42 (3.21)
6-Minute Walk Testb 656.89 (63.30) 644.02 (63.30) 678.62 (73.27) 638.64 (57.44) 628.33 (60.44) 643.39 (54.00)
MET-minutes/weekc 1333.66 (1367.67) 1621.12 (1734.42) 2105.63 (2104.75) 1138.00 (1148.81) 1018.97 (1396.25) 1844.94 (1555.35)
aFatigue scores ranging from 6 to 30.
bReported in meters.
cSelf-reported physical activity level (International Physical Activity Questionnaire short form) measured in metabolic equivalent of task (MET) minutes.
Table 3: Tests of baseline–end of chemotherapy (Post1) changes.
Time (baseline–Post1) Time × condition
df 𝐹 value 𝑃 value df 𝐹 value 𝑃 value
Schwartz Cancer Fatigue Scale-6a 1/58 9.604 0.003∗ 1/58 0.001 0.970
6-Minute Walk Testb 1/57 3.005 0.088 1/57 0.036 0.849
MET-minutes/weekc 1/56 0.125 0.725 1/56 0.727 0.398
∗
<0.05.
aFatigue scores ranging from 6–30.
bReported in meters.
cSelf-reported physical activity level (International Physical Activity Questionnaire-short form) measured in metabolic equivalent of task (MET) minutes.
perform moderate to vigorous physical activity (MVPA) 150
minutes/week [1]. In this study self-reported mean physical
activity levels in both groupsmet the generally recommended
weekly MVPA, and the study sample exercised according to
a moderate activity level as measured in MET-minutes/week.
Results could thus reflect that both groups exercised enough
to relief negative effects of chemotherapy on the studied
outcomes and that the scheduled exercise intervention did
not give additional effect.
The findings of this trial should be interpreted with
caution due to some limitations. The employed research
design does not make it possible to control for changes in
the effects of cancer therapy on dependent variables over
time. Although elevated levels of cancer-related fatigue and
reduced physical fitness and activity levels should be expected
also six months after chemotherapy [32], one cannot rule
out that diminishing side effects of chemotherapy could
explain the results. A possible explanation why participants
in the intervention group did not achieve effects beyond
the control group at this point of measurement could be
the relative small difference in exercise volume between
the two groups. If the present exercise intervention was
to counteract cancer-related fatigue and maintain physical
fitness and physical activity levels more completely also
during chemotherapy, better adherence to the program is
probably necessary. Adherence is a critical component to
the success of an exercise program and has been identified
as a challenge in exercise intervention research, influencing
treatment outcome and effectiveness [33, 34]. Low adherence
rates might also reflect deficiency of the exercise prescription
applied in this study [35] and the exercise environment
with lack of supervision and behavioral change techniques
[36–38]. Exercise adherence could have been increased by
greater attention to the principles of building progression
in the exercise program [35], and to apply individual goal
setting based on the patient’s reaction to chemotherapy.
However, previous research evidence concerning the exercise
dose sufficient to maintain physical activity and effectively
counteract fatigue in all phases of breast cancer treatment is
sparse and calls for more research.
Of note, an accrual rate of 72% of eligible patients is
a strength of this study and is slightly higher compared
to previous exercise research studies among cancer popula-
tions range, <40–57% [39]. High accrual rates increase the
representativeness of the sample, ensuring external validity
[40]. Also, an acceptable drop-out rate within the range
(9–21%) reported in exercise interventions to breast cancer
populations was obtained [38].The issue on drop-outs in ran-
domized control trials is especially a challenge for statistical
conclusion validity.The sample was homogeneous at baseline
and at Post
2
, which indicates that results are not affected by
selection bias [41].
5. Conclusion
In summary, our hypothesis of additional effects of a home-
based moderate-intensity exercise intervention performed
by breast cancer patients during adjuvant chemotherapy
treatment was not supported. Instead, the findings suggest
that generally recommended physical activity levels of 150
minutes/week of moderate to vigorous physical activity [1]
is enough to sufficiently relieve cancer-related fatigue and
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Table 4: Tests of baseline–follow-up (Post2) changes.
Time (Baseline–Post2) Time × condition
df 𝐹 value 𝑃 value df 𝐹 value 𝑃 value
Schwartz Cancer Fatigue Scale-6a 1/50 1.512 0.181 1/50 0.398 0.463
6-Minute Walk Testb 1/49 6.957 0.009∗ 1/49 1.383 0.245
MET-minutes/weekc 1/48 14.77 0.000∗ 1/48 0.105 0.747
∗
<0.05.
aScore range 6–30.
bReported in meters.
cSelf-reported physical activity level (International Physical Activity Questionnaire-short form) measured in metabolic equivalent of task (MET) minutes.
restore physical fitness and activity levels. Although it should
be taken into consideration that the fatigue experience might
have been reduced due to passing of time since chemotherapy,
clinicians should routinely communicate to patients that
being physicaly active on a regular basis can be beneficial
to improve health and well-being. The results of this study
can be used to guide nursing professionals to inform and
motivate women with breast cancer to initiate and maintain
exercise as a health behavior during chemotherapy according
to guidelines provided for breast cancer populations.
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